Vasiliki Kalatzis

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7001909/vasiliki-kalatzis-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

63 papers	2,653 citations	25 h-index	51 g-index
70 ext. papers	2,950 ext. citations	5.9 avg, IF	4.44 L-index

#	Paper	IF	Citations
63	iPSCs for modeling choroideremia **2022**, 123-151		
62	Identification of the First Single Exon 8 Structural Variants Associated with Autosomal Dominant Hearing Loss.. *Diagnostics*, **2022**, 12,	3.8	0
61	Generation of a human iPSC line, INMi005-A, from a patient with non-syndromic USH2A-associated retinitis pigmentosa.. *Stem Cell Research*, **2022**, 60, 102738	1.6	0
60	Molecular Therapy for Choroideremia: Pre-clinical and Clinical Progress to Date. *Molecular Diagnosis and Therapy*, **2021**, 25, 661-675	4.5	
59	Novel roles for voltage-gated T-type Ca and ClC-2 channels in phagocytosis and angiogenic factor balance identified in human iPSC-derived RPE. *FASEB Journal*, **2021**, 35, e21406	0.9	1
58	Allele-Specific Knockout by CRISPR/Cas to Treat Autosomal Dominant Retinitis Pigmentosa Caused by the G56R Mutation in NR2E3. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	5
57	CRISPR/Cas9-Mediated Genome Editing to Generate Clonal iPSC Lines. *Methods in Molecular Biology*, **2021**, 1	1.4	1
56	Preclinical pharmacology of a lipophenol in a mouse model of light-induced retinopathy. *Experimental and Molecular Medicine*, **2020**, 52, 1090-1101	12.8	6
55	Study of Usutu virus neuropathogenicity in mice and human cellular models. *PLoS Neglected Tropical Diseases*, **2020**, 14, e0008223	4.8	12
54	Genome Editing in Patient iPSCs Corrects the Most Prevalent Mutations and Reveals Intriguing Mutant mRNA Expression Profiles. *Molecular Therapy - Methods and Clinical Development*, **2020**, 17, 156-173	6.4	35
53	A Novel Chromosomal Translocation Identified due to Complex Genetic Instability in iPSC Generated for Choroideremia. *Cells*, **2019**, 8,	7.9	4
52	Nonsense-mediated mRNA decay efficiency varies in choroideremia providing a target to boost small molecule therapeutics. *Human Molecular Genetics*, **2019**, 28, 1865-1871	5.6	14
51	Generation of a human iPSC line, INMi003-A, with a missense mutation in CRX associated with autosomal dominant cone-rod dystrophy. *Stem Cell Research*, **2019**, 38, 101478	1.6	3
50	Generation of a human iPSC line, INMi004-A, with a point mutation in CRX associated with autosomal dominant Leber congenital amaurosis. *Stem Cell Research*, **2019**, 38, 101476	1.6	2
49	Genome Editing as a Treatment for the Most Prevalent Causative Genes of Autosomal Dominant Retinitis Pigmentosa. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	25
48	Zika virus induces strong inflammatory responses and impairs homeostasis and function of the human retinal pigment epithelium. *EBioMedicine*, **2019**, 39, 315-331	8.8	20
47	Pathogenicity of novel atypical variants leading to choroideremia as determined by functional analyses. *Human Mutation*, **2019**, 40, 31-35	4.7	7

46	Dietary, environmental, and genetic risk factors of Extensive Macular Atrophy with Pseudodrusen, a severe bilateral macular atrophy of middle-aged patients. *Scientific Reports*, **2018**, 8, 6840	4.9	4
45	Guiding Lights in Genome Editing for Inherited Retinal Disorders: Implications for Gene and Cell Therapy. *Neural Plasticity*, **2018**, 2018, 5056279	3.3	25
44	Exogenous LRRK2G2019S induces parkinsonian-like pathology in a nonhuman primate. *JCI Insight*, **2018**, 3,	9.9	19
43	Generation of a human iPSC line, INMi002-A, carrying the most prevalent USH2A variant associated with Usher syndrome type 2. *Stem Cell Research*, **2018**, 33, 247-250	1.6	3
42	Lysosomal and network alterations in human mucopolysaccharidosis type VII iPSC-derived neurons. *Scientific Reports*, **2018**, 8, 16644	4.9	10
41	Generation of an iPSC line, INMi001-A, carrying the two most common USH2A mutations from a compound heterozygote with non-syndromic retinitis pigmentosa. *Stem Cell Research*, **2018**, 33, 228-232	1.6	4
40	The effect of PTC124 on choroideremia fibroblasts and iPSC-derived RPE raises considerations for therapy. *Scientific Reports*, **2018**, 8, 8234	4.9	21
39	Zika Virus Efficiently Replicates in Human Retinal Epithelium and Disturbs Its Permeability. *Journal of Virology*, **2017**, 91,	6.6	20
38	Pathogenicity of a novel missense variant associated with choroideremia and its impact on gene replacement therapy. *Human Molecular Genetics*, **2017**, 26, 3573-3584	5.6	22
37	Functional rescue of REP1 following treatment with PTC124 and novel derivative PTC-414 in human choroideremia fibroblasts and the nonsense-mediated zebrafish model. *Human Molecular Genetics*, **2016**, 25, 3416-3431	5.6	54
36	A Comprehensive Analysis of Choroideremia: From Genetic Characterization to Clinical Practice. *PLoS ONE*, **2016**, 11, e0151943	3.7	37
35	Clinical Evaluation and Cone Alterations in Choroideremia. *Ophthalmology*, **2016**, 123, 1830-1832	7.3	22
34	Cultured Cells from the Human Oocyte Cumulus Niche Are Efficient Feeders to Propagate Pluripotent Stem Cells. *Stem Cells and Development*, **2015**, 24, 2317-27	4.4	6
33	Corrective GUSB transfer to the canine mucopolysaccharidosis VII brain. *Molecular Therapy*, **2014**, 22, 762-73	11.7	19
32	Corrective GUSB transfer to the canine mucopolysaccharidosis VII cornea using a helper-dependent canine adenovirus vector. *Journal of Controlled Release*, **2014**, 181, 22-31	11.7	15
31	Proof of concept for AAV2/5-mediated gene therapy in iPSC-derived retinal pigment epithelium of a choroideremia patient. *Molecular Therapy - Methods and Clinical Development*, **2014**, 1, 14011	6.4	52
30	Side scatter intensity is highly heterogeneous in undifferentiated pluripotent stem cells and predicts clonogenic self-renewal. *Stem Cells and Development*, **2013**, 22, 1851-60	4.4	18
29	Corneal transduction by intra-stromal injection of AAV vectors in vivo in the mouse and ex vivo in human explants. *PLoS ONE*, **2012**, 7, e35318	3.7	31

28	Screening for a canine model of choroideremia exclusively identifies nonpathogenic CHM variants. *Ophthalmic Research*, **2011**, 45, 155-63	2.9	4
27	Renal phenotype of the cystinosis mouse model is dependent upon genetic background. *Nephrology Dialysis Transplantation*, **2010**, 25, 1059-66	4.3	68
26	Hereditary Cystinosis **2009**, 661-679		1
25	Cystine accumulation in the CNS results in severe age-related memory deficits. *Neurobiology of Aging*, **2009**, 30, 987-1000	5.6	16
24	The cell adhesion molecule "CAR" and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution. *PLoS Pathogens*, **2009**, 5, e1000277	7.6	100
23	Gene transfer may be preventive but not curative for a lysosomal transport disorder. *Molecular Therapy*, **2008**, 16, 1372-81	11.7	13
22	The ocular anomalies in a cystinosis animal model mimic disease pathogenesis. *Pediatric Research*, **2007**, 62, 156-62	3.2	25
21	Molecular pathogenesis of cystinosis: effect of CTNS mutations on the transport activity and subcellular localization of cystinosin. *Human Molecular Genetics*, **2004**, 13, 1361-71	5.6	93
20	New aspects of the pathogenesis of cystinosis. *Pediatric Nephrology*, **2003**, 18, 207-15	3.2	52
19	Identification of 14 novel CTNS mutations and characterization of seven splice site mutations associated with cystinosis. *Human Mutation*, **2002**, 20, 439-46	4.7	46
18	Immunolocalization of cystinosin, the protein defective in cystinosis. *Journal of the American Society of Nephrology: JASN*, **2002**, 13, 2046-51	12.7	28
17	Cystinosis: from gene to disease. *Nephrology Dialysis Transplantation*, **2002**, 17, 1883-6	4.3	28
16	Intralysosomal cystine accumulation in mice lacking cystinosin, the protein defective in cystinosis. *Molecular and Cellular Biology*, **2002**, 22, 7622-32	4.8	130
15	Cystinosin, the protein defective in cystinosis, is a H(+)-driven lysosomal cystine transporter. *EMBO Journal*, **2001**, 20, 5940-9	13	213
14	The targeting of cystinosin to the lysosomal membrane requires a tyrosine-based signal and a novel sorting motif. *Journal of Biological Chemistry*, **2001**, 276, 13314-21	5.4	98
13	Characterization of a putative founder mutation that accounts for the high incidence of cystinosis in Brittany. *Journal of the American Society of Nephrology: JASN*, **2001**, 12, 2170-2174	12.7	24
12	Branchio-Oto-Renal syndrome. *Advances in Oto-Rhino-Laryngology*, **2000**, 56, 39-44	1.7	4
11	Identification and characterisation of the murine homologue of the gene responsible for cystinosis, Ctns. *BMC Genomics*, **2000**, 1, 2	4.5	10

10	Branchio-otic syndromes imbroglio **1999**, 82, 440-441		3
9	Eya1 expression in the developing ear and kidney: towards the understanding of the pathogenesis of Branchio-Oto-Renal (BOR) syndrome. *Developmental Dynamics*, **1998**, 213, 486-99	2.9	90
8	The fundamental and medical impacts of recent progress in research on hereditary hearing loss. *Human Molecular Genetics*, **1998**, 7, 1589-97	5.6	61
7	Clustering of mutations responsible for branchio-oto-renal (BOR) syndrome in the eyes absent homologous region (eyaHR) of EYA1. *Human Molecular Genetics*, **1997**, 6, 2247-55	5.6	160
6	A human homologue of the Drosophila eyes absent gene underlies branchio-oto-renal (BOR) syndrome and identifies a novel gene family. *Nature Genetics*, **1997**, 15, 157-64	36.3	566
5	BOR and BO Syndromes Are Allelic Defects of EYA1. *European Journal of Human Genetics*, **1997**, 5, 242-246	3.3	92
4	Characterization of a translocation-associated deletion defines the candidate region for the gene responsible for branchio-oto-renal syndrome. *Genomics*, **1996**, 34, 422-5	4.3	21
3	A proposed new contiguous gene syndrome on 8q consists of Branchio-Oto-Renal (BOR) syndrome, Duane syndrome, a dominant form of hydrocephalus and trapeze aplasia; implications for the mapping of the BOR gene. *Human Molecular Genetics*, **1994**, 3, 1859-66	5.6	105
2	Mapping of the chromosome 11 breakpoint of the t(4;11)(q21;p14-15) translocation. *Cancer Genetics and Cytogenetics*, **1993**, 69, 122-5		2
1	The gene for the human IgA Fc receptor maps to 19q13.4. *Human Genetics*, **1992**, 89, 107-8	6.3	51